Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of dextromethorphan hydrobromide to treatment of acute and chronic renal fibrosis

A technology for dextromethorphan hydrobromide and renal fibrosis, which is applied in the direction of medical preparations containing active ingredients, organic active ingredients, drug delivery, etc., to achieve the effect of preventing and inhibiting the weakening of renal function

Active Publication Date: 2017-10-20
ZHEJIANG UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, the research on the mechanism of RIF development is the key to find targets for delaying or reversing the progression of CKD, but currently there is no effective treatment for clinical application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of dextromethorphan hydrobromide to treatment of acute and chronic renal fibrosis
  • Application of dextromethorphan hydrobromide to treatment of acute and chronic renal fibrosis
  • Application of dextromethorphan hydrobromide to treatment of acute and chronic renal fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Embodiment 1, configure dextromethorphan hydrobromide injection.

[0026] Dextromethorphan hydrobromide (molecular formula C 18 h 25 NO·HBr·H 2 O, referred to as DXM), white powder, purchased from Sigma-Aldrich Company. Take 100mg of DXM powder, dissolve it with normal saline to 10ml, and prepare a 10mg / ml mother solution. Before use, take 0.5ml, 1.5ml, and 3ml of the mother solution, dilute it with normal saline to 10ml, and prepare 0.5mg / ml, 1.5mg / ml, and 3mg / ml injections for low, medium, and Drug use in the high-dose group.

Embodiment 2

[0027] Example 2, test preparation.

[0028] 8-week-old healthy male C57BL / 6 mice were purchased from the Experimental Animal Center of Zhejiang University, and the right renal artery was clamped and opened for 45 minutes to cause ischemia-reperfusion injury of the right kidney and lead to chronic renal fibrosis. Two weeks after ischemia / reperfusion, mice were randomly divided into 4 groups, sham operation group (Control), ischemia-reperfusion (IR) group, IR+low dose (5 mg / kg, LD) group, IR+medium dose (15 mg / kg, MD) group, IR+high dose (30 mg / kg, HD) group, 8 rats in each group. The sham operation group was given normal drinking water.

Embodiment 3

[0029] Example 3, verifying the effect of DXM on reducing serum creatinine in ischemic mice.

[0030] On the basis of Example 2, after ischemia, the mouse serum creatinine was measured every two weeks, and the results were significantly different using GraphPad Prism 7.0 for Two-way ANOVA analysis, the results are as follows figure 1 It was shown that the serum creatinine of renal ischemia mice before medication was significantly higher than that of the sham operation group; after 2 weeks (4wk) of medication, the serum creatinine of mice in the high-dose group decreased first, which was significantly lower than that of the non-medication group; after 4 weeks of medication (6wk) After 6 weeks (8wk) and 6 weeks (8wk), the high, medium and low doses all have a significant down-regulation effect on the serum creatinine value of mice, and there is a certain dose effect. .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of dextromethorphan hydrobromide to treatment of acute and chronic renal fibrosis. The molecular formula of dextromethorphan hydrobromide is C18H25NO HBr H2O. The dextromethorphan hydrobromide has the shape of white powder and the dosage form of injection; the injection is obtained after diluting mother liquid prepared from dextromethorphan hydrobromide powder and physiological saline. The invention provides the application of the existing medicine (dextromethorphan hydrobromide) to the treatment of the acute and chronic renal fibrosis. The technical scheme and the technical effect can prove that the dextromethorphan hydrobromide can be used for effectively preventing and inhibiting the long-period prognostic renal function weakening and renal fibrosis due to renal ischaemia; the ingredients can be used for medium-long-period renal function protection after the acute kidney injury; the novel scheme is provided for the acute chronic renal fibrosis; the novel direction is provided for the medicine study of the dextromethorphan hydrobromide.

Description

technical field [0001] The present invention relates to a new application of dextromethorphan hydrobromide (DXM), especially the treatment plan and application for treating acute and chronic renal fibrosis. Background technique [0002] The incidence of chronic kidney disease (CKD) in my country is about 10.8%. With the further aggravation of population aging and other problems, its threat to public health and the burden it brings to society have become increasingly prominent. CKD patients have a significantly higher risk of cardiovascular and cerebrovascular diseases, infections, etc., and can lose labor force or even die due to complications before developing end-stage renal disease (ESRD). Renal interstitial fibrosis is a characteristic pathological change of CKD, manifested as pathological fibrous matrix deposition in renal tubules and peritubes, is a common path of CKD progression and a sign of poor prognosis, and its severity is a determinant of renal function deterior...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/485A61K9/08A61P13/12
CPCA61K9/0019A61K9/08A61K31/485A61K47/02
Inventor 沈佳陈江华王仁定周静怡
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com